The COVID-19 crisis has transformed the healthcare ecosystem in just a few months. It has prevented patients to consult their doctor in person and use Telehealth or remote monitoring when possible. Clinical study sites have been put on hold, accelerating remote trials. Medical congresses have migrated online to a large extend. Sales representatives have been and are still stranded at home for a large part. While the share of digital activities that remain when the crisis is over will depend on country, channel, therapy area, or HCP preference, the Omni-Channel transformation is here for good.
It is time for Pharma and MedTech companies to prepare for a new Go-To-Market strategy, where digital is seamlessly integrated into an aligned Omni-Channel approach.
